News | July 04, 2025
Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Granules India receives 1 observation from USFDA for Chantilly facility
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Subscribe To Our Newsletter & Stay Updated
